DORFSTRASSE 29, ZUG, V8
Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
MoonLake Immunotherapeutics Enters Underwriting Agreement for $75 Million Off...
Reports on Week 16 Results of the VELA Phase 3 Hidradenitis Suppurativa Program with the Nanobody® Sonelokimab
Reports Second Quarter 2025 Financial Results and Provides a Business Update
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence